Arvinas (Nasdaq: ARVN) has announced a change in its commercial leadership, with John Northcott stepping down from his role as chief commercial officer, due to personal reasons.
Mr Northcott, who joined Arvinas in 2022 as its first-ever CCO, played an important role in establishing the Connecticut, USA-based firm’s nascent commercial operation.
Filling the role on an interim basis is Alex Santini, who currently serves as senior VP for market access. Mr Santini joined Arvinas in early 2023 and brings over three decades of experience in commercial leadership positions at companies including Lexicon Pharmaceuticals (Nasdaq: LXRX), Bayer (BAYN: DE), and Nektar Therapeutics (Nasdaq: NKTR).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze